Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:33 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 13,729 matching trials from the live ClinicalTrials.gov search.
Filters: Baltimore, Maryland Clear all
Completed Phase 3 Interventional Results available

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

NCT00762034
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pemetrexed, Paclitaxel, Carboplatin, Bevacizumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
67
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Alhambra, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 2 Interventional

ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects

NCT03687632
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Indianapolis, Indiana • Edgewood, Kentucky • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Nov 1, 2026, 5:33 AM EST
Terminated Phase 3 Interventional Results available

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

NCT05211947
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 51 Years
Enrollment
1,356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
49
States / cities
Anaheim, California • Bellflower, California • Culver City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Withdrawn Phase 1 Interventional

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02861040
View directory record Official record
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Vincristine Sulfate Liposome, Volasertib
Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Palo Alto, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Nov 1, 2026, 5:33 AM EST
Terminated Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

NCT05543252
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Minzasolmin (UCB0599)
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 78 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
41
States / cities
Phoenix, Arizona • Fountain Valley, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers

NCT01673555
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Nov 1, 2026, 5:33 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy

NCT05756426
View directory record Official record
Conditions
Hemorrhage, Hemodynamic Instability
Interventions
Prospective
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Completed Not applicable Interventional

Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis

NCT04054050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Light therapy
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 1 Interventional

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02029950
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia-2, High Risk Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Cytarabine, Daunorubicin Hydrochloride, Etoposide, Idarubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Nov 1, 2026, 5:33 AM EST
Completed No phase listed Observational

An Open Label Data Collection Study of My Connect Post-Op, a Post-Operative Communication Tool

NCT07120191
View directory record Official record
Conditions
Total Hip Replacement, Total Knee Replacement
Interventions
post op communication software
Device
Lead sponsor
Concentra AI, inc
Industry
Eligibility
22 Years to 80 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Wichita, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Withdrawn Not applicable Interventional

Neurostimulation for the Treatment of Post-Operative Ileus

NCT00854074
View directory record Official record
Conditions
Ileus
Interventions
ElectroCore RMS-1100 Resolution Motility System™
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

NCT03719690
View directory record Official record
Conditions
HRAS Gene Mutation, HNSCC
Interventions
Tipifarnib, HRAS Detection Assay
Drug · Device
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
29
States / cities
Los Angeles, California • San Francisco, California • Whittier, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Nov 1, 2026, 5:33 AM EST
Withdrawn Not applicable Interventional

Improving Sensitivity of Urine Cytology for Bladder Cancer

NCT01826097
View directory record Official record
Conditions
Bladder Cancer
Interventions
La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 4 Interventional Results available

Reducing Total Cardiovascular Risk in an Urban Community

NCT00241904
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus, Atherosclerosis, Cerebral Arteriosclerosis, Hypertension
Interventions
Lifestyle Changes, Antiplatelet Agents, Beta Blocker, ACE Inhibitors
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 2 Interventional

Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery

NCT00617552
View directory record Official record
Conditions
Postoperative Ileus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2012 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044408
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
13
States / cities
Long Beach, California • Norwalk, Connecticut • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

NCT02201940
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Nov 1, 2026, 5:33 AM EST
Completed Not applicable Interventional

TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance

NCT00023374
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifampin, Pyrazinamide, Ethambutol, REZ
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 1 Interventional

Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits

NCT00181090
View directory record Official record
Conditions
Epilepsy
Interventions
Modified Atkins diet
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 3 Interventional Results available

Study of Antidepressants in Parkinson's Disease

NCT00086190
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
paroxetine, venlafaxine, placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
15
States / cities
San Francisco, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Nov 1, 2026, 5:33 AM EST
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response - II (PARes-II)

NCT01894555
View directory record Official record
Conditions
Atherothrombosis
Interventions
Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Nov 1, 2026, 5:33 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

NCT02291055
View directory record Official record
Conditions
Cervical Cancer, Cancer, Head and Neck Cancer
Interventions
ADXS11-001, MEDI4736
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Nov 1, 2026, 5:33 AM EST
Terminated Phase 3 Interventional

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

NCT05018585
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo
Biological · Dietary Supplement
Lead sponsor
Diamyd Medical AB
Industry
Eligibility
12 Years to 28 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Newport Beach, California • Palo Alto, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 1, 2026, 5:33 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants

NCT07818915
View directory record Official record
Conditions
HIV Infections
Interventions
VH4367310, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 1, 2026, 5:33 AM EST